UK Markets open in 7 hrs 26 mins

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
100.35-0.24 (-0.24%)
At close: 4:00PM EST
Sign in to post a message.
  • f
    Curevac posts positive clinical trials on covid-19 vaccine.
    (ABM Financial News,, Binckbank 13.21 Hr CET).
  • M
    CVAC gets a boost from BAYER, that's BIG BIG BIG!
  • L
    $BNTX conversation
    2020 is over !

    The vaccine sector has been pummelled over the last 20-30 days ! #CVAC, #NVAX, #MDRA and #BTNX etc are all down. The upside for #BTNX becomes even greater everyday the usual suspects drop the price of #BTNX. In the beginning I would imagine many mid size investors diversified and positioned in all the vaccine stocks months ago. Over the last month they have been cashing in on big gains in this sector for the year. This created a retail selling frenzy and a downward spiral. I am assuming this is temporary and we should start seeing a positive reaction in the new year due to the huge upside this turmoil has created. I am long in this stock from October and will continue to be long in the new year. There is risk, but I believe the reward is greater now then ever before.

    Happy New Year and see you all in 2021.
  • C
    It's ripe for a big run...
  • F
    We going 160$ next days don't miss the rally on curevac
  • E
    I sold CVAC on Friday with a little loss and moved to MRNA & BNTX....
  • J
    I think it’s hilarious that some people think COVID is an isolated event. We are going to have a COVID vaccine every year, just like the flu. There are billions and billions of people, who need to get vaccinated just for this year alone! Several billion will need to be vaccinated next year, and the following year, etc! This stock and others are only going up with time. MRNA Is able to be adjusted quickly, it’s effective and it doesn’t have to be kept in a special freezer. This is vaccine can be distributed with ease. If you have the money, hold and buy the dips...This one is going up with time 2021-2022. Big movement in options expected. His should be the runner
  • M
    CVAC bet is looking better every day! CVAC might be the big winner in the vaccine race. BNTX vaccine is way too hard to handle, just talk to any pro. They are eagerly awaiting CVAC to deploy their product into all corners of the world. Plus, it's government backed and has a huge pipeline. MRNA is too expensive. My money is on CVAC!
  • n
    never again
    If Elon Musk is involved, im hanging around just for s&g....
  • H
  • C
    CVAC may recover from this morning's loss COB today.
  • E
    CVAC back to $150 guys!
    CVAC MRNA BNTXAI are 4 of a kind....
  • S
    what. is going on? 8-9% drops every day?
  • P
    (ARDS) MCap $60 m /FLOAT 6 m / Covid Phase 3 Data within Weeks /Under radar stock=1000%++ UPSIDEE

    Continued enrolling global Phase 3 clinical trial of AR-301 in patients with ventilator associated pneumonia (VAP) including patients who presented with VAP secondary to ventilator placement for COVID-19. Interim futility analysis is expected in 1H 2021; full data is expected in YE 2021.

  • E
    May see $20 up today!
  • T
    why the drop last 2 days>?
  • e
    Is this going to phase 3 before year end? I read they planned on phase 3 before close of the year ? Thanks for advice -
  • E
    Entrepreneur Germany
    Please help: Why CureVac is going that much up without having a product on the street.
  • E
    Check news on INO ---->>>
  • A
    It will be interesting to see if today's upgrade is enough to propel the stock even higher.

    Following the upgrade, the most recent consensus for CureVac from its four analysts is for revenues of US$91m in 2020 which, if met, would be a sizeable 421% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 98% to US$2.37. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$74m and losses of US$3.72 per share in 2020. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.